Table 5.
Two-way fixed effects regression by drug (class), specialization, and outcome; associations with PA measures for biosimilar prescribing, controlling for physician and time fixed effects, all physicians, and balanced panel, 2009–2015.
| Biologic Drug (Class) | Outcome | Biosimilar Share (Prescriptions) | Prescriptions Biosimilars |
Prescriptions Original |
Prescriptions Total |
||||
|---|---|---|---|---|---|---|---|---|---|
| Type of Measure | GP | Specialist | GP | Specialist | GP | Specialist | GP | Specialist | |
| ESAs (n = 15,506 (GPs), n = 50,389 (specialists)) |
Priority prescribing | −0.0161 | −0.0230 * | −1.7419 * | −6.8939 * | −0.6267 | −4.1181 | −2.3686 | −11.0120 * |
| (0.0180) | (0.0106) | (0.8732) | (3.4506) | (1.3009) | (3.2010) | (1.7723) | (4.9739) | ||
| Quota | −0.0044 | 0.0247 *** | −0.5899 | 8.5505 ** | −1.3458 | 2.2037 | −1.9357 | 10.7542 * | |
| (0.0148) | (0.0075) | (1.4571) | (2.7040) | (1.9901) | (2.7980) | (2.9063) | (4.3682) | ||
| Filgrastim (n = 3021 (GPs), n = 14,758 (specialists)) |
Priority prescribing | −0.0196 | −0.0055 | 0.2571 | 3.3308 * | 0.903 | 0.6469 | 1.1601 | 3.9777 * |
| (0.0361) | (0.0126) | (0.8610) | (1.6303) | (0.6409) | (1.2059) | (0.9966) | (1.9138) | ||
| Quota | −0.1228 | 0.0442 | 2.1511 | −1.3236 | 8.313 | −1.1173 | 10.464 | −2.4409 | |
| (0.1073) | (0.0319) | (1.1118) | (3.5723) | (6.9305) | (1.8316) | (7.2926) | (4.4568) | ||
| Somatropin (n = 1436 (GPs), n = 7392 (specialists)) |
Priority prescribing | 0.0055 | −0.0018 | 0.0834 | 0.069 | 0.7486 | −10.5695 | 0.832 | −10.5005 |
| (0.0231) | (0.0087) | (0.1211) | (1.8285) | (1.3554) | (11.9035) | (1.4192) | (13.1738) | ||
| Quota | −0.0224 | 0.0136 | 0.0997 | 0.4783 | 1.6937 | −12.3819 | 1.7933 | −11.9036 | |
| (0.0340) | (0.0106) | (0.1958) | (1.6254) | (2.3429) | (11.4075) | (2.490) | (12.3867) | ||
ESAs: Erythropoesis-stimulating agents; GP: general practitioner; ***: p < 0.01; **: p < 0.05; *: p < 0.1, standard errors are in parentheses.